NovoCure Ltd (NVCR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 250M 500M 750M FY13: 10.4M FY14: 15.5M FY15: 33.1M FY16: 82.9M FY17: 177M FY18: 248.1M FY19: 351.3M FY20: 494.4M FY21: 535M FY22: 537.8M FY23: 509.3M FY24: 605.2M FY25: 655.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 200M 400M 600M FY13: 3.3M FY14: 5.5M FY15: 12.5M FY16: 36.6M FY17: 121.4M FY18: 168M FY19: 262.7M FY20: 387.9M FY21: 420.2M FY22: 423M FY23: 381.1M FY24: 468M FY25: 488.5M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-240M -160M -80M 0 80M 160M 240M FY13: -64.5M FY14: -80.2M FY15: -104M FY16: -115.3M FY17: -39.3M FY18: -33.7M FY19: -914K FY20: 30.4M FY21: -44.3M FY22: -89.5M FY23: -232.9M FY24: -170.5M FY25: -153.8M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-240M -160M -80M 0 80M 160M 240M FY13: -77.4M FY14: -80.7M FY15: -111.6M FY16: -131.8M FY17: -61.7M FY18: -63.6M FY19: -7.2M FY20: 19.8M FY21: -58.4M FY22: -92.5M FY23: -207M FY24: -168.6M FY25: -136.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 60M 120M 180M FY13: 7M FY14: 10M FY15: 20.6M FY16: 39.9M FY17: 55.6M FY18: 80M FY19: 88.6M FY20: 106.5M FY21: 114.9M FY22: 114.9M FY23: 128.3M FY24: 137.2M FY25: 166.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY13: -52.7M FY14: -74.2M FY15: -99.9M FY16: -107.6M FY17: -33.1M FY18: -1.9M FY19: 26.6M FY20: 99.1M FY21: 82.8M FY22: 30.8M FY23: -73.3M FY24: -26.4M FY25: -49M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY13: -54.9M FY14: -75.1M FY15: -104.6M FY16: -113.3M FY17: -40.5M FY18: -8.6M FY19: 16.1M FY20: 84.2M FY21: 58.6M FY22: 9.4M FY23: -100.4M FY24: -69.2M FY25: -75.7M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY18: 91.8M FY19: 97.2M FY20: 108.9M FY21: 103.4M FY22: 104.7M FY23: 106.4M FY24: 107.8M FY25: 111.5M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q2 '15: -7.37 Q3 '15: -8.01 Q4 '15: -6.61 Q1 '16: -5.26 Q2 '16: -3.38 Q3 '16: -1.68 Q4 '16: -1.55 Q1 '17: -1.34 Q2 '17: -1.10 Q3 '17: -0.84 Q4 '17: -0.70 Q1 '18: -0.72 Q2 '18: -0.65 Q3 '18: -0.65 Q4 '18: -0.70 Q1 '19: -0.60 Q2 '19: -0.44 Q3 '19: -0.29 Q4 '19: -0.08 Q1 '20: 0.09 Q2 '20: 0.12 Q3 '20: 0.19 Q4 '20: 0.19 Q1 '21: 0.11 Q2 '21: -0.05 Q3 '21: -0.27 Q4 '21: -0.56 Q1 '22: -0.56 Q2 '22: -0.65 Q3 '22: -0.77 Q4 '22: -0.88 Q1 '23: -1.34 Q2 '23: -1.65 Q3 '23: -1.86 Q4 '23: -1.94 Q1 '24: -1.80 Q2 '24: -1.57 Q3 '24: -1.39 Q4 '24: -1.56 Q1 '25: -1.51 Q2 '25: -1.56 Q3 '25: -1.61 Q4 '25: -1.22 Q1 '26: -1.53 Q2 '26: -1.30 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.